[ad_1]
jurgenfr
Gilead Sciences (NASDAQ:GILD) is predicted to report the next This autumn revenue on decrease income Tuesday night, with buyers watching to see how the corporate’s Hepatitis C and HIV franchises are faring.
Analysts, on common, estimate Gilead will put up an adjusted revenue of $1.76 per share, in contrast with $1.67 for a similar quarter in 2022. Income is anticipated at $7.10B, down from $7.39B the prior yr.
For Q3 2023, Gilead reported comparatively flat year-over-year income due partially to decrease gross sales of its HCV merchandise and COVID-19 remedy Veklury, often known as remdesivir. Sure HIV medicine additionally underperformed. Regardless of slowed gross sales, the corporate nonetheless managed to beat the Road on the highest and backside strains.
Gilead has exceeded Road income estimates for the previous 8 quarters. It’s managed to high EPS estimates 5 occasions, however has missed 3 occasions. Over the previous 90 days, 22 analysts have raised their This autumn estimates for the corporate, whereas 2 have lowered them.
Gilead watchers may also be seeking to see if the corporate achieves the 2023 forecast it issued in Q3. The corporate raised its full-year gross sales outlook to the vary of $26.7B to $26.9B, up from its prior view of $26.3B to $26.7B. The gross sales estimate for Veklury was raised to $1.9B from $1.7B.
Analysts, on common, anticipate Gilead to report 2023 income of $27.08B.
[ad_2]
Source link
